Dr. Ronald Aung-Din to discuss power of patented Direct Effects Technology™ combined with CBD and its effect on neuropsychiatric disorders
DECEMBER 7, 2017 – LAS VEGAS – Isodiol International Inc. (CSE: ISOL) (OTC:ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and nutraceutical products, announced today that Dr. Ronald Aung-Din, Medical, Science and Development Advisor at Isodiol, will present at the 25th Annual American Academy of Anti-Aging Medicine (A4M) World Congress being held at the Venetian/Palazzo Resort in Las Vegas, December 14-16.
Dr. Aung-Din, a board-certified neurologist with more than 35 years of experience in general neurology and neuro-psychiatry, will take the stage to discuss how Direct Effects Technology™ has refashioned the application of CBD for those suffering from conditions such as Parkinson’s disease, peripheral neuropathy and cluster headaches. Direct Effects is a patented non-systemic delivery system utilized in Isodiol’s IsoDerm™ Direct Effects Cream. The topical is applied to the back of the neck at the hairline, where it is picked up by the free nerve endings located in the dermis of the skin for a highly effective delivery of the compound.
“We have long been working with neurologists and physicians in Brazil to bring relief to patients using this technology and look forward to having our newly appointed advisor, Dr. Aung-Din, share the science behind Direct Effects with A4M attendees,” said Marcos Agramont, CEO of Isodiol. “Direct Effects has made IsoDerm™ more effective for those suffering from neurological, psychiatric, and physical pain. We plan to develop further products utilizing the Direct Effects delivery method.”
The speaking engagement follows Isodiol’s announcement that the company has acquired the global rights for the patented Direct Effects Technology. The licensing rights apply to IsoDerm™, as well as five other propriety pharmaceutical compounds to be delivered by the Direct Effects system. The official press release can be viewed here.
IsoDerm™ Direct Effects Cream, along with Isodiol’s diverse product line which includes non-cannabis CBD tablets, transdermal patches, and CBD-infused beverages, will be exhibited during the event at BOOTH 4085.
About Isodiol International Inc.
Isodiol Internatonal Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia, and Europe.
ON BEHALF OF THE BOARD
“Marcos Agramont” CEO & Director
COMPANY MEDIA :
North 6th Agency
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.